NO975938L - Anti-fedme proteiner - Google Patents

Anti-fedme proteiner

Info

Publication number
NO975938L
NO975938L NO975938A NO975938A NO975938L NO 975938 L NO975938 L NO 975938L NO 975938 A NO975938 A NO 975938A NO 975938 A NO975938 A NO 975938A NO 975938 L NO975938 L NO 975938L
Authority
NO
Norway
Prior art keywords
obesity
obesity proteins
proteins
disability
diabetes
Prior art date
Application number
NO975938A
Other languages
English (en)
Other versions
NO975938D0 (no
Inventor
John Michael Beals
Ronald Eugene Chance
James Arthur Hoffmann
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of NO975938D0 publication Critical patent/NO975938D0/no
Publication of NO975938L publication Critical patent/NO975938L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/5759—Products of obesity genes, e.g. leptin, obese (OB), tub, fat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/106—Plasmid DNA for vertebrates
    • C12N2800/107—Plasmid DNA for vertebrates for mammalian

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Child & Adolescent Psychology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

Det blir beskrevet antifedmeproteiner som når de blir administrert til en pasient, regule- rer fettvev. Følgelig, tillater slike midler pasientene å overvinne sine fedmehandicap og leve normale liv med sterkt redusert risiko for type 2 diabetes, kardiovaskulær sykdom og cancer.
NO975938A 1996-12-20 1997-12-17 Anti-fedme proteiner NO975938L (no)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US3356196P 1996-12-20 1996-12-20

Publications (2)

Publication Number Publication Date
NO975938D0 NO975938D0 (no) 1997-12-17
NO975938L true NO975938L (no) 1998-06-22

Family

ID=21871119

Family Applications (1)

Application Number Title Priority Date Filing Date
NO975938A NO975938L (no) 1996-12-20 1997-12-17 Anti-fedme proteiner

Country Status (23)

Country Link
EP (1) EP0849276A1 (no)
JP (1) JPH10179158A (no)
KR (1) KR19980064258A (no)
CN (1) CN1194986A (no)
AR (1) AR013886A1 (no)
AU (2) AU4843297A (no)
BR (1) BR9706358A (no)
CA (1) CA2217698A1 (no)
CO (1) CO4700343A1 (no)
CZ (1) CZ407097A3 (no)
HU (1) HUP9702500A3 (no)
ID (1) ID19257A (no)
IL (1) IL122569A0 (no)
NO (1) NO975938L (no)
NZ (1) NZ329413A (no)
PE (1) PE47599A1 (no)
PL (1) PL323956A1 (no)
SG (1) SG65040A1 (no)
SV (1) SV1997000107A (no)
TR (1) TR199701666A3 (no)
WO (1) WO1998028335A1 (no)
YU (1) YU48997A (no)
ZA (1) ZA9710877B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE422359T1 (de) 1997-04-15 2009-02-15 Csir Verbindungen und pharmazeutische zusammensetzungen mit appetitunterdrückender aktivität
WO1999044598A2 (en) * 1998-03-03 1999-09-10 Board Of Regents, The University Of Texas System Methods for inhibiting βcell apoptosis
GB9924484D0 (en) * 1999-10-15 1999-12-15 Isis Innovation Altered polypeptide aggregation
GB2396815B (en) 1999-10-27 2004-09-08 Phytopharm Plc A composition comprising a pregnenone derivative and an NSAID
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
GB2363985B (en) 2000-06-30 2004-09-29 Phytopharm Plc Extracts,compounds & pharmaceutical compositions having anti-diabetic activity and their use
JP5031827B2 (ja) 2006-06-01 2012-09-26 程云 予防或いは肝損傷を治療するペプチッド
WO2025240494A1 (en) * 2024-05-13 2025-11-20 Lumen Bioscience, Inc. Leptin compositions and methods of making and using the same to support weight loss and/or maintenance

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6309853B1 (en) * 1994-08-17 2001-10-30 The Rockfeller University Modulators of body weight, corresponding nucleic acids and proteins, and diagnostic and therapeutic uses thereof
US5827734A (en) * 1995-01-20 1998-10-27 University Of Washington Materials and methods for determining ob protein in a biological sample
CA2211664A1 (en) * 1995-01-31 1996-08-08 Eli Lilly And Company Anti-obesity proteins
AU4862396A (en) * 1995-02-06 1996-08-27 Eli Lilly And Company Human obesity gene
WO1996031526A1 (en) * 1995-04-06 1996-10-10 Amylin Pharmaceuticals, Inc. Anti-obesity agents
GB9509164D0 (en) * 1995-05-05 1995-06-28 Smithkline Beecham Plc Novel compounds
CA2224867A1 (en) * 1995-06-22 1997-01-09 Eli Lilly And Company Obesity protein intermediates and their preparation and use

Also Published As

Publication number Publication date
CO4700343A1 (es) 1998-12-29
PL323956A1 (en) 1998-06-22
NO975938D0 (no) 1997-12-17
ID19257A (id) 1998-06-28
CA2217698A1 (en) 1998-06-20
AR013886A1 (es) 2001-01-31
NZ329413A (en) 1999-10-28
TR199701666A2 (xx) 1999-10-21
YU48997A (sh) 1999-09-27
CN1194986A (zh) 1998-10-07
SG65040A1 (en) 1999-05-25
ZA9710877B (en) 1999-06-03
JPH10179158A (ja) 1998-07-07
HUP9702500A2 (hu) 1998-07-28
KR19980064258A (ko) 1998-10-07
BR9706358A (pt) 1999-05-04
IL122569A0 (en) 1998-06-15
AU5384698A (en) 1998-07-17
AU4843297A (en) 1998-06-25
HUP9702500A3 (en) 1999-07-28
PE47599A1 (es) 1999-05-14
SV1997000107A (es) 1999-01-18
WO1998028335A1 (en) 1998-07-02
CZ407097A3 (cs) 1998-07-15
HU9702500D0 (en) 1998-03-02
EP0849276A1 (en) 1998-06-24
TR199701666A3 (tr) 1999-10-21

Similar Documents

Publication Publication Date Title
ATE239474T1 (de) Verwendung von levobupivacain
Hosie et al. Managing hypertension in general practice: can we do better?
AR052921A1 (es) Uso de ranolazina para la preparacion de una composicion farmaceutica y composicion farmaceutica
DK0944396T3 (da) Præparater og fremgangsmåder til forøgelse af tarmfunktion
BR0015974A (pt) Uso de levetiracetam, composição farmacêutica, uso de uma composição farmacêutica e métodos para tratar um paciente admintstrado com uma quantidade de pelo menos um composto e uma doença e para potenciar seletivamente o efeito terapêutico de um composto
BR9607336A (pt) Composições de aminoácidos e utilidades das mesmas em nutrição clinica
ATE263571T1 (de) Verwendung von erythropoietin und eisenpräparaten zur herstellung von pharmazeutischen kombinationspräparaten zur behandlung von rheumatischen erkrankungen
WO2003062273A3 (en) Modulator of the notch signalling pathway and use thereof in medical treatment
BRPI0414215A (pt) tienopirazóis
DK0981347T3 (da) Anvendelsen af levobupivacain i ansigtkirurgi
BR9814075A (pt) Método de tratamento da doença de alzheimer
SV1997000107A (es) Proteinas anti-obesidad
IT1317927B1 (it) Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patologie autoimmuni.
PT1408977E (pt) Terapia de combinacao para o tratamento de falha cardiaca
BR0108261A (pt) Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono
MD970254A (en) Use of melatonine for treatment of patients having a medicamental dependence
IT1317930B1 (it) Uso della pentraxina lunga ptx3 per la preparazione di un medicamentoper il trattamento di patalogie associate ad una alterata attivazione
NO973515L (no) Anti-fedme proteiner
BR9713514A (pt) Novo uso de creatina
BR9707776A (pt) Utilização da il-7 no tratamento das doenças autoimunes em especial o diabetes mellitus dependente de insulina
DK0588477T3 (da) Medicinsk præparat omfatende TCF-11
BR0014803A (pt) Peptìdeo, composição farmacêutica, uso de um ou mais dos peptìdeos, e, composição de diagnóstico
BR9808866A (pt) Moléculas retinóicas relacionadas à inibição da superprodução de endotelina-1 em doenças
MX9705832A (es) Proteinas contra la obesidad.
ES2189213T3 (es) Utilizacion de un compuesto de tipo retinoide para aumentar in vivo la actividad de desacoplamiento de la proteina ucp2.

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application